Gastrointestinal devices for the treatment of type 2 diabetes

Brethauer, Stacy A.; Chang, Julietta; Neto, Manoel Galvao; Greve, Jan

doi:10.1016/j.soard.2016.02.031

Cited by 9 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous studies confirm the effectiveness of bariatric methods in the reduction of body mass and glucose level in blood. Moreover, the improvement in heart and metabolic profile in obese children was also reported [21][22][23].…”

Section: Discussionmentioning

confidence: 69%

“…Attention should be paid to the reduction of the surface of visceral adipose tissue, which highly correlates with the development of metabolic diseases [20]. Similar profits from using BIB treatment were observed by scientists from other countries [21][22][23]. The consequences of obesity for the function of cardiovascular system mainly depend on the distribution of adipose tissue.…”

Section: Discussionmentioning

confidence: 88%

See 1 more Smart Citation

Assessment of the Effect of Dietary Modifications and Bioenteric Intragastric Balloon Treatment on the Changes of Some Morphological and Biochemical Parameters in Obese Patients

Balejko

Plust

2018

Ann Nutr Metab

View full text Add to dashboard Cite

Obesity is the most common disease of affluence of the XXI century. According to WHO (World Health Organization), it is defined as a chronic metabolic disorder manifested by excessive accumulation of adipose tissue with high tendency for familial occurrence. According to WHO, obesity reaches epidemic proportions in many countries. High BMI (Body Mass Index) correlates with coexisting diseases. Traditional dietetic treatment often does not bring any results. A form of conservative (non-surgical) support for patients in fighting with obesity is the reduction of stomach volume by bioenteric intragastric balloon (BIB) treatment. The aim of the work was to develop a diet with anti-inflammatory properties, well-tolerated by the patients after BIB treatment. An American diet was modified by changing the composition of fatty acids, increasing anti-oxidative potential and adding synbiotics for patients treated with BIB. Chemical analysis of reconstructed food ratios of recommended diet was performed, analysing the content of micronutrients, composition of fatty acids, antioxidative capacity, reducing power and the content of polyphenols. Improvement in anthropometric measurement results and satisfying body weight loss were obtained, while preserving fat-free body mass. Improvement in the parameters of lipid metabolism was also observed, that is, decrease in total CH (cholesterol) and TG (triglycerides), and normalized concentration of HDL (high density lipoproteins) and LDL (low density lipoproteins) fractions. Reduced concentration of glucose in blood and lower blood pressure was also noted. Performed study confirms the effectiveness of complex treatment with BIB and properly adjusted individualized diet. Observations and own experience allow to deduce that patients who resign from systematic contact with a dietician cannot maintain reduced body weight. Abandoning previous habits is the only way to maintain the effect of weight loss. Most importantly, the change in patients’ awareness and consequent behaviour in the future are crucial. Even though genes may contribute to obesity, environmental factors mainly determine the possibility of the disease to occur. Therefore, the change of patients’ lifestyle after body weight reduction will decide on their fate.

show abstract

Section: Discussionmentioning

confidence: 69%

Section: Discussionmentioning

confidence: 88%

Assessment of the Effect of Dietary Modifications and Bioenteric Intragastric Balloon Treatment on the Changes of Some Morphological and Biochemical Parameters in Obese Patients

Balejko

Plust

2018

Ann Nutr Metab

View full text Add to dashboard Cite

show abstract

“…Our previous concern[ 29 ] that specialized training is needed for the use of these devices appears to be supported by three warnings (in February 2017, August 2017, and June 2018) from the United States Food and Drug Administration with regards to issues related to intragastric balloons including multiple deaths related to intragastric balloons. Two major reviews in the past two years examined the 30+ year experience with intragastric balloons[ 30 , 31 ]. Brethauer et al[ 30 ] concluded that more study was required in patients with type 2 diabetes mellitus.…”

Section: Bariatric Endoscopic Proceduresmentioning

confidence: 99%

“…Two major reviews in the past two years examined the 30+ year experience with intragastric balloons[ 30 , 31 ]. Brethauer et al[ 30 ] concluded that more study was required in patients with type 2 diabetes mellitus. Popov et al[ 31 ] concluded that intragastric balloons were more effective that diet alone for an initial improvement of metabolic risk factors, but that their conclusions are limited by the small number of participants and the lack of long-term follow-up data.…”

Section: Bariatric Endoscopic Proceduresmentioning

confidence: 99%

Current and future impact of clinical gastrointestinal research on patient care in diabetes mellitus

Koch

Shope

Camilleri

2018

WJD

View full text Add to dashboard Cite

The worldwide rise in the prevalence of obesity supports the need for an increased interaction between ongoing clinical research in the allied fields of gastrointestinal medicine/surgery and diabetes mellitus. There have been a number of clinically-relevant advances in diabetes, obesity, and metabolic syndrome emanating from gastroenterological research. Gastric emptying is a significant factor in the development of upper gastrointestinal symptoms. However, it is not the only mechanism whereby such symptoms occur in patients with diabetes. Disorders of intrinsic pacing are involved in the control of stomach motility in patients with gastroparesis; on the other hand, there is limited impact of glycemic control on gastric emptying in patients with established diabetic gastroparesis. Upper gastrointestinal functions related to emptying and satiations are significantly associated with weight gain in obesity. Medications used in the treatment of diabetes or metabolic syndrome, particularly those related to pancreatic hormones and incretins affect upper gastrointestinal tract function and reduce hyperglycemia and facilitate weight loss. The degree of gastric emptying delay is significantly correlated with the weight loss in response to liraglutide, a glucagon-like peptide-1 analog. Network meta-analysis shows that liraglutide is one of the two most efficacious medical treatments of obesity, the other being the combination treatment phentermine-topiramate. Interventional therapies for the joint management of obesity and diabetes mellitus include newer endoscopic procedures, which require long-term follow-up and bariatric surgical procedure for which long-term follow up shows advantages for individuals with diabetes. Newer bariatric procedures are presently undergoing clinical evaluation. On the horizon, combination therapies, in part directed at gastrointestinal functions, appear promising for these indications. Ongoing and future gastroenterological research when translated to care of individuals with diabetes mellitus should provide additional options to improve their clinical outcomes.

show abstract

“…Several reviews have been published in examining the 30+ year experience in the utilization of intragastric balloons. A 2016 review from the Cleveland Clinic [29] concluded that additional studies were needed with regards to the role in individuals with type 2 diabetes of intragastric balloons. A 2017 review from New York University [30] described the availability of small studies with short follow ups that made it difficult to evaluate metabolic risk factors in individuals who had undergone treatment with intragastric balloons.…”

mentioning

confidence: 99%